Critical role for white blood cell NAD(P)H oxidase-mediated plasminogen activator inhibitor-1 oxidation and ventricular rupture following acute myocardial infarction

Journal of Molecular and Cellular Cardiology

Volumn 50, Issue 3, 2011, Pages 426-432

  Agarwal, Udit ^a,b   Zhou, Xiaorong ^a   Weber, Kristal ^a   Dadabayev, Alisher R ^a   Penn, Marc S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b KENT STATE UNIVERSITY   (United States)

Author keywords

Inflammation; Myocardial rupture; Oxidation

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE; MYELOPEROXIDASE; OXIDOREDUCTASE; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN P47PHOX; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; CORONARY ARTERY LIGATION; ENZYME ACTIVITY; GENE SILENCING; HEART RUPTURE; HEART VENTRICLE RUPTURE; LEUKOCYTE; MALE; MOUSE; NITRATION; NONHUMAN; OXIDATION; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME;

ANIMALS; BONE MARROW TRANSPLANTATION; HEART RUPTURE; HEART RUPTURE, POST-INFARCTION; HEART VENTRICLES; LEUKOCYTES; MALE; MICE; MICE, KNOCKOUT; NADPH OXIDASE; NITRIC OXIDE SYNTHASE TYPE II; OXIDATION-REDUCTION; PEROXIDASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; VENTRICULAR REMODELING;

MUS;

EID: 79551602731     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2010.08.024     Document Type: Article

References (26)

1. Przyklenk K., Connelly C.M., McLaughlin R.J., Kloner R.A., Apstein C.S. Effect of myocyte necrosis on strength, strain, and stiffness of isolated myocardial strips. Am Heart J 1987, 114:1349-1359.
2. Penn M.S. The role of leukocyte-generated oxidants in left ventricular remodeling. Am J Cardiol 2008, 101:30D-33D.
3. Heymans S., Luttun A., Nuyens D., Theilmeier G., Creemers E., Moons L., et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 1999, 5:1135-1142.
4. Moriwaki H., Stempien-Otero A., Kremen M., Cozen A.E., Dichek D.A. Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice. Circ Res 2004, 95:637-644.
5. Askari A., Brennan M.L., Zhou X., Drinko J., Morehead A., Thomas J.T., et al. Myeloperoxidase and plasminogen activator inhibitor-1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med 2003, 197:615-624.
6. Strandberg L., Lawrence D.A., Johansson L.B., Ny T. The oxidative inactivation of plasminogen activator inhibitor type 1 results from a conformational change in the molecule and does not require the involvement of the P1' methionine. J Biol Chem 1991, 266:13852-13858.
7. Sigurdardottir O., Wiman B. Identification of a PAI-1 binding site in vitronectin. Biochim Biophys Acta 1994, 1208:104-110.
8. phox for left ventricular remodeling/dysfunction and survival after myocardial infarction. Circ Res 2007, 100:894-903.
9. Liu Y.H., Carretero O.A., Cingolani O.H., Liao T.D., Sun Y., Xu J., et al. Role of inducible nitric oxide synthase in cardiac function and remodeling in mice with heart failure due to myocardial infarction. Am J Physiol Heart Circ Physiol 2005, 289:H2616-H2623.
10. Ito M., Adachi T., Pimentel D.R., Ido Y., Colucci W.S. Statins inhibit beta-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes via a Rac1-dependent mechanism. Circulation 2004, 110:412-418.
11. Mazurier F., Doedens M., Gan O.I., Dick J.E. Rapid myeloerythroid repopulation after intrafemoral transplantation of NOD-SCID mice reveals a new class of human stem cells. Nat Med 2003, 9:959-963.
12. Vasilyev N., Williams T., Brennan M.L., Unzek S., Zhou X., Heinecke J.W., et al. Myeloperoxidase-generated oxidants modulate left ventricular remodeling but not infarct size after myocardial infarction. Circulation 2005, 112:2812-2820.
13. Arndt P.G., Young S.K., Poch K.R., Nick J.A., Falk S., Schrier R.W., et al. Systemic inhibition of the angiotensin-converting enzyme limits lipopolysaccharide-induced lung neutrophil recruitment through both bradykinin and angiotensin II-regulated pathways. J Immunol 2006, 177:7233-7241.
14. Thorsen S., Mullertz S., Suenson E., Kok P. Sequence of formation of molecular forms of plasminogen and plasmin-inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator. Biochem J 1984, 223:179-187.
15. Kohler H.P., Grant P.J. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000, 342:1792-1801.
16. Gong Y., Hart E., Shchurin A., Hoover-Plow J. Inflammatory macrophage migration requires MMP-9 activation by plasminogen in mice. J Clin Invest 2008, 118:3012-3024.
17. Liu Z., Li N., Diaz L.A., Shipley M., Senior R.M., Werb Z. Synergy between a plasminogen cascade and MMP-9 in autoimmune disease. J Clin Invest 2005, 115:879-887.
18. Barnes J.L., Mitchell R.J., Torres E.S. Expression of plasminogen activator-inhibitor-1 (PAI-1) during cellular remodeling in proliferative glomerulonephritis in the rat. J Histochem Cytochem 1995, 43:895-905.
19. Park Y.J., Liu G., Lorne E.F., Zhao X., Wang J., Tsuruta Y., et al. PAI-1 inhibits neutrophil efferocytosis. Proc Natl Acad Sci USA 2008, 105:11784-11789.
20. Wojta J., Kaun C., Zorn G., Ghannadan M., Hauswirth A.W., Sperr W.R., et al. C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils. Blood 2002, 100:517-523.
21. Yang F., Liu Y.H., Yang X.P., Xu J., Kapke A., Carretero O.A. Myocardial infarction and cardiac remodelling in mice. Exp Physiol 2002, 87:547-555.
22. Zaman A.K., Fujii S., Schneider D.J., Taatjes D.J., Lijnen H.R., Sobel B.E. Deleterious effects of lack of cardiac PAI-1 after coronary occlusion in mice and their pathophysiologic determinants. Histochem Cell Biol 2007, 128:135-145.
23. Looi Y.H., Grieve D.J., Siva A., Walker S.J., Anilkumar N., Cave A.C., et al. Involvement of Nox2 NADPH oxidase in adverse cardiac remodeling after myocardial infarction. Hypertension 2008, 51:319-325.
24. Teshima Y., Yufu K., Akioka H., Iwao T., Anan F., Nakagawa M., et al. Early atorvastatin therapy improves cardiac function in patients with acute myocardial infarction. J Cardiol 2009, 53:58-64.
25. Kanadasi M., Cayli M., Demirtas M., Inal T., Demir M., Koc M., et al. The effect of early statin treatment on inflammation and cardiac events in acute coronary syndrome patients with low-density lipoprotein cholesterol. Heart Vessels 2006, 21:291-297.
26. Gurgun C., Ildizli M., Yavuzgil O., Sin A., Apaydin A., Cinar C., et al. The effects of short term statin treatment on left ventricular function and inflammatory markers in patients with chronic heart failure. Int J Cardiol 2008, 123:102-107.